Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, Mori T, Hidaka K, Kuwano M
Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.
Br J Cancer. 1995 Aug;72(2):418-23. doi: 10.1038/bjc.1995.348.
Multidrug resistance phenotypes in human tumours are associated with the overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene, and also with that of the non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATP-binding protein. We have previously reported that overexpression of MRP appears to be responsible for spontaneous multidrug resistance in some human glioma cell lines (Abe et al., Int. J. Cancer, 58, 860-864, 1994). In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscoclaurine alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also reverse multidrug resistance in human glioma cells. The glioma cell lines were the two MRP-expressing cell lines, T98G and IN500, an MDR1-expressing cell line, CCF-STTG1, and the MRP1 MDR1-non-expressing cell line, IN157. Verapamil and NIK250 almost completely reversed drug resistance to vincristine, etoposide and doxorubicin in T98G cells, while they also reversed drug resistance to vincristine and etoposide, but only partially to doxorubicin in IN500 cells. Cepharanthine as well as verapamil and NIK250 reversed vincristine resistance in CCF-STTG1 cells, but cepharanthine only partially reversed drug resistance in T98G and IN500 cells. The cellular accumulation of [3H]etoposide increased about 2- and 3-fold compared with control in T98G cells in the presence of verapamil and NIK250 respectively. Furthermore, the release of doxorubicin from the nuclei of T98G cells was blocked by NIK250. However, NIK250 and verapamil caused no apparent increase in vincristine accumulation in T98G cells. NIK250 or verapamil might exert inhibitory effects upon MRP function, resulting in a reversal of MRP-mediated spontaneous multidrug resistance in cultured human glioma cells.
人类肿瘤中的多药耐药表型与多药耐药1(MDR1)基因编码的170 kDa P-糖蛋白的过表达有关,也与非P-糖蛋白介导的多药耐药基因MRP的过表达有关,该基因编码一种190 kDa的膜ATP结合蛋白。我们之前报道过,MRP的过表达似乎是某些人类胶质瘤细胞系中自发多药耐药的原因(Abe等人,《国际癌症杂志》,58卷,860 - 864页,1994年)。在本研究中,我们调查了P-糖蛋白介导的多药耐药的化学增敏剂,如维拉帕米、一种双苄基异喹啉生物碱(粉防己碱)和一种二氢吡啶类似物(NIK250)是否也能逆转人类胶质瘤细胞中的多药耐药。胶质瘤细胞系包括两个表达MRP的细胞系T98G和IN500、一个表达MDR1的细胞系CCF - STTG1以及不表达MRP和MDR1的细胞系IN157。维拉帕米和NIK250几乎完全逆转了T98G细胞对长春新碱、依托泊苷和阿霉素的耐药性,而它们也逆转了IN500细胞对长春新碱和依托泊苷的耐药性,但对阿霉素的耐药性仅部分逆转。粉防己碱以及维拉帕米和NIK250逆转了CCF - STTG1细胞对长春新碱的耐药性,但粉防己碱仅部分逆转了T98G和IN500细胞的耐药性。在维拉帕米和NIK250存在的情况下,T98G细胞中[³H]依托泊苷的细胞内蓄积分别比对照增加了约2倍和3倍。此外,如果NIK250存在,T98G细胞核中的阿霉素释放会受阻。然而,NIK250和维拉帕米并未使T98G细胞中长春新碱的蓄积明显增加。NIK250或维拉帕米可能对MRP功能产生抑制作用,从而导致培养的人类胶质瘤细胞中MRP介导的自发多药耐药性得到逆转。